Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ponesimod

ponesimod

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of ponesimod

2 trials tracked of ponesimod: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 217 citations.

2Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2
  1. Phase 3 Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis Completed · 217 cited
  2. Phase 3 Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis Completed

Showing the 2 most-cited and recently-updated of 2 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Ponesimod Shows Sustained Efficacy and Safety in RMS Over 5 Years
Neurology RCT
Ponesimod Shows Sustained Efficacy and Safety in RMS Over 5 Years Could Ponesimod Change the Game for Multiple Sclerosis Patients?
In a 5-year extension of the OPTIMUM study, ponesimod 20 mg maintained a lower ARR (0.143) compared to teriflunomide switchers (0.184).
After five years, nearly half of people taking ponesimod for multiple sclerosis had no relapses, offering more stable lives with fewer unexp…
Mar 27, 2026